The progressive decrease of the costs of the new technologies for genomic analysis is a positive trend that gives hope for the adoption of pharmacogenetic and pharmacogenomic profiling in clinical practice in the short-to-medium term.
← all excerpts
Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.
1
—
—